Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS ...
An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics and the elderly. The researchers behind the innovative treatment say that ...
Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback